Walter Haught, MD
Cardiovascular Disease · Huntsville, ALNPI 1700856200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Novartis at 24.8% of the total.
Across 229 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$523
- Pfizer$514
- Regeneron Healthcare Solutions, Inc.$308
- E.r. Squibb & Sons, L.L.C.$266
- Johnson & Johnson$232
- plus $2K from 21 others
Across 74 payments — averaging $21,817 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.3M
- AstraZeneca$244K
- Novartis$32K
- Astrazeneca UK Limited$30K
- Amarin Pharma, Inc.$26K
- Vifor (international) Ltd.$19K
- plus $4K from 2 others
What the payments were for
- Food & beverage$4,533100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 66 | $1,125 |
| Amgen | 28 | $523 |
| Pfizer | 29 | $514 |
| Regeneron Healthcare Solutions, Inc. | 14 | $308 |
| E.r. Squibb & Sons, L.L.C. | 12 | $266 |
| Johnson & Johnson | 13 | $232 |
| AstraZeneca | 10 | $210 |
| Merck | 9 | $188 |
| Novo Nordisk | 2 | $140 |
| Actelion Pharmaceuticals US, Inc. | 7 | $138 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| Esperion Therapeutics, Inc. | 5 | $101 |
| Endotronix, Inc. | 1 | $98 |
| Bayer | 4 | $76 |
| Abbott | 3 | $73 |
| Scpharmaceuticals Inc. | 4 | $72 |
| Medtronic | 1 | $70 |
| Boehringer Ingelheim | 3 | $57 |
| Siemens Medical Solutions USA, Inc. | 3 | $55 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $40 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Procyrion, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Recor Medical Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Gilead | 1 | $13 |
How this compares
$4,533 in reported general payments places this provider in the 60th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 637 | $620,877 |
| EntrestoSacubitril/Valsartan | 215 | $223,475 |
| XareltoRivaroxaban | 143 | $163,817 |
| MultaqDronedarone Hcl | 90 | $105,994 |
| Repatha SureclickEvolocumab | 57 | $48,364 |
| JardianceEmpagliflozin | 20 | $22,733 |
| Metoprolol Succinate | 643 | $13,673 |
| Ranolazine ErRanolazine | 70 | $9,358 |
| Atorvastatin Calcium | 568 | $7,505 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 36 | $7,014 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 83 | $5,397 |
| Flecainide Acetate | 90 | $5,160 |
| Carvedilol | 401 | $4,234 |
| Rosuvastatin Calcium | 193 | $3,602 |
| Ezetimibe | 107 | $3,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $514 | $620,877637 claims |
| NovartisEntresto | $1,125 | $223,475215 claims |
| Johnson & JohnsonXarelto | $232 | $163,817143 claims |
| Sanofi-aventis U.S. LLCMultaq | $114 | $105,99490 claims |
| Boehringer IngelheimJardiance | $57 | $22,73320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Huntsville
- James MurphyHuntsville$18K
- Enrique VelasquezHuntsville$14K
- Warren FosterHuntsville$13K
- Warren StricklandHuntsville$11K
- Joshusa ValtosHuntsville$11K
- Sadasiva KattaHuntsville$10K
- Christian DeutschHuntsville$9K
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.